Abstract
MicroRNAs (miRNA), small noncoding RNA molecules, are endogenous regulators of gene expression that have been implicated in the pathogenesis of various diseases such as cancer and arthritis. The aim of this study was to explore the biological function of microRNA-16-5p (miR-16-5p) and the molecular mechanism in osteoarthritis (OA). MiRNA targets were identified using bioinformatics. Using real-time PCR, the expression of miR-16-5p and SMAD3 in cartilage specimens was determined in 10 patients with knee OA and in 10 traumatic amputees (control). Functional analysis of miR-16-5p in chondrocytes was performed at both mRNA and protein levels after miRNA transfection. A luciferase reporter assay was used to verify interaction between miRNA and target mRNA. Expression of miR-16-5p was significantly higher in OA cartilages than in healthy cartilages. The data from the reporter assay and western blots indicated that miR-16- 5p regulated SMAD3 expression. Functional analysis showed that miR-16-5p could reduce expression of type IIcollagen and aggrecan while inducing expression of matrix metalloproteinases and ADAMTS; however, miR-16-5p inhibition could reverse these effects. Our results indicate that miR-16-5p is an important regulator of SMAD3 expression in human chondrocytes and may contribute to the development of OA.
Keywords: miR-16-5p, SMAD3, osteoarthritis, chondrocytes.
Current Pharmaceutical Design
Title:MicroRNA-16-5p Controls Development of Osteoarthritis by Targeting SMAD3 in Chondrocytes
Volume: 21 Issue: 35
Author(s): Lisong Li, Jie Jia, Xianzhe Liu, Shuhua Yang, Shunan Ye, Wen Yang and Yukun Zhang
Affiliation:
Keywords: miR-16-5p, SMAD3, osteoarthritis, chondrocytes.
Abstract: MicroRNAs (miRNA), small noncoding RNA molecules, are endogenous regulators of gene expression that have been implicated in the pathogenesis of various diseases such as cancer and arthritis. The aim of this study was to explore the biological function of microRNA-16-5p (miR-16-5p) and the molecular mechanism in osteoarthritis (OA). MiRNA targets were identified using bioinformatics. Using real-time PCR, the expression of miR-16-5p and SMAD3 in cartilage specimens was determined in 10 patients with knee OA and in 10 traumatic amputees (control). Functional analysis of miR-16-5p in chondrocytes was performed at both mRNA and protein levels after miRNA transfection. A luciferase reporter assay was used to verify interaction between miRNA and target mRNA. Expression of miR-16-5p was significantly higher in OA cartilages than in healthy cartilages. The data from the reporter assay and western blots indicated that miR-16- 5p regulated SMAD3 expression. Functional analysis showed that miR-16-5p could reduce expression of type IIcollagen and aggrecan while inducing expression of matrix metalloproteinases and ADAMTS; however, miR-16-5p inhibition could reverse these effects. Our results indicate that miR-16-5p is an important regulator of SMAD3 expression in human chondrocytes and may contribute to the development of OA.
Export Options
About this article
Cite this article as:
Li Lisong, Jia Jie, Liu Xianzhe, Yang Shuhua, Ye Shunan, Yang Wen and Zhang Yukun, MicroRNA-16-5p Controls Development of Osteoarthritis by Targeting SMAD3 in Chondrocytes, Current Pharmaceutical Design 2015; 21 (35) . https://dx.doi.org/10.2174/1381612821666150909094712
DOI https://dx.doi.org/10.2174/1381612821666150909094712 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Emerging Anabolic Treatments in Osteoporosis
Current Drug Safety The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets The Role of Neuronal Insulin/Insulin-Like Growth Factor-1 Signaling for the Pathogenesis of Alzheimer’s Disease: Possible Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Anticancer Activity of the Ascidian Polyclinum Indicum against Cervical Cancer Cells (HeLa) Mediated through Apoptosis Induction
Medicinal Chemistry Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Stress Relaxation Testing of Non-Small Lung Cancer Cells Using Atomic Force Microscopy
Current Nanoscience Recent Research in Selective Cyclin-Dependent Kinase 4 Inhibitors for Anti-Cancer Treatment
Current Medicinal Chemistry Recent Advances in Gene Therapy of Endometriosis
Recent Patents on DNA & Gene Sequences MicroRNAs and Bone Regeneration
Current Genomics Last Findings on Dual Inhibitors of Abl and Src Tyrosine-Kinases
Mini-Reviews in Medicinal Chemistry DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Angiogenesis as a Treatment Strategy for Neuroblastoma
Current Cancer Therapy Reviews The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets LncRNA, Important Player in Bone Development and Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets